<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01130532</url>
  </required_header>
  <id_info>
    <org_study_id>13461</org_study_id>
    <secondary_id>H6D-US-LVIP</secondary_id>
    <nct_id>NCT01130532</nct_id>
  </id_info>
  <brief_title>A Study in Erectile Dysfunction</brief_title>
  <official_title>Tadalafil Once Daily Following As-Needed Phosphodiesterase Type 5 Inhibitor Treatment, an Assessment of Return to Normal Erectile Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to evaluate if treatment with tadalafil once daily will allow
      men to return to normal erectile function in those who did not have normal erectile function
      following as-needed (PRN) Phosphodiesterase Type 5 (PDE5) Inhibitor treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Having an International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score Greater Than or Equal to 26 Through 12-Week Endpoint (Double-Blind Treatment Period)</measure>
    <time_frame>Baseline through 12 weeks</time_frame>
    <description>Self-reported erectile function over the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (low/no erectile function) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Data presented are the percentage of participants who return to normal erectile function (IIEF-EF domain score â‰¥26) at end of double-blind treatment period (Period III).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12-Week Endpoint in the International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Self-reported erectile function over the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (low/no erectile function) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12-Week Endpoint in the International Index of Erectile Function - Intercourse Satisfaction (IIEF-IS) Domain Score</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Self-reported intercourse satisfaction over the past 4 weeks. IIEF-IS is the sum of Questions 6, 7 and 8 of the IIEF. Scores range from 0 (low/no satisfaction) to 5 (high satisfaction) for each question, with the total possible score for the 3 questions of 0 to 15. Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12-Week Endpoint in the International Index of Erectile Function - Overall Satisfaction (IIEF-OS) Domain Score</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Self-reported overall satisfaction over the past 4 weeks. IIEF-OS is the sum of Questions 13 and 14; each question scored as 1 (low/no satisfaction) through 5 (high satisfaction) with total subscore for the 2 questions of 2 to 10. Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12-Week in Percentage of &quot;Yes&quot; Responses to Sexual Encounter Profile (SEP) Questions 1-5</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Assessed was the mean change from baseline in the percentage of Yes responses to the SEP diary Questions 1-5. Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12-Week Endpoint in Treatment Satisfaction Scale (TSS) - Patient</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>The TSS measured participant satisfaction with treatment based on a 13-item questionnaire. The overall score for each of five TSS domains (confidence to complete sexual activity, ease of erection, pleasure from sexual activity, erectile function satisfaction, and satisfaction with orgasm) was converted to a 0-100 scale with higher numbers on the scale indicating greater satisfaction. Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Satisfaction Scale (TSS) - Patient Satisfaction With Medication Score at Week 12 Endpoint</measure>
    <time_frame>Week 12</time_frame>
    <description>The TSS - patient satisfaction with medication measured participant satisfaction with treatment based on a 13-item questionnaire. The overall score was converted to a 0-100 scale with higher numbers on the scale indicating greater satisfaction. Satisfaction with medication was analyzed using analysis of covariance (ANOVA). The model included factors of study, treatment group, and pooled site within study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12-Week Endpoint in the International Index of Erectile Function (IIEF) Question 15 (Sexual Confidence)</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Self-reported erectile function over the past 4 weeks. Question 15, confidence in the ability to get an erection, is scored from 1 (very low confidence) to 5 (very high confidence). Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12-Week Endpoint in Treatment Satisfaction Scale (TSS) - Partner</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>The TSS measured participant's partner satisfaction with treatment based on a 13-item questionnaire. The overall score for each of five TSS domains (confidence to complete sexual activity, ease of erection, pleasure from sexual activity, erectile function satisfaction, and satisfaction with orgasm) was converted to a 0-100 scale with higher numbers on the scale indicating greater satisfaction. Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Satisfaction Scale (TSS) - Partner Satisfaction With Medication Score at Week 12 Endpoint</measure>
    <time_frame>Week 12</time_frame>
    <description>The TSS - partner satisfaction with medication measured participant's partner satisfaction with treatment based on a 13-item questionnaire. The overall score was converted to a 0-100 scale with higher numbers on the scale indicating greater satisfaction. Satisfaction with medication was analyzed using analysis of covariance (ANOVA). The model included factors of study, treatment group, and pooled site within study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Having International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score Greater Than or Equal to 26 From 12 to 16 Weeks</measure>
    <time_frame>12 weeks through 16 weeks</time_frame>
    <description>Self-reported erectile function over the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (low/no erectile function) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Data presented are the percentage of participants who return to normal erectile function (IIEF-EF domain score â‰¥26) at end of open-label extension treatment period (Period IV).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From 12 Weeks to 16 Weeks in Participant's International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score</measure>
    <time_frame>12 weeks and 16 weeks</time_frame>
    <description>Self-reported erectile function over the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (low/no erectile function) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Week 12 to Week 16 Percentage of &quot;Yes&quot; Responses to Sexual Encounter Profile (SEP) Questions 3</measure>
    <time_frame>12 weeks and 16 weeks</time_frame>
    <description>Assessed the percentage of Yes responses to the SEP diary Question 3 &quot;Did your erection last long enough for you to have successful intercourse?&quot; from Week 12 (end of double-Blind treatment) to Week 16 (end of open-label treatment).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">623</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>2.5 milligram (mg) titrated to 5 mg Tadalafil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2.5 mg for 4 weeks, followed by 5 mg for 8 weeks with option to continue treatment at 5 mg for an additional 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 mg Tadalafil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5.0 mg for 12 weeks with option to continue treatment for additional 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tadalafil</intervention_name>
    <description>Administer orally</description>
    <arm_group_label>2.5 milligram (mg) titrated to 5 mg Tadalafil</arm_group_label>
    <arm_group_label>5 mg Tadalafil</arm_group_label>
    <other_name>Cialis</other_name>
    <other_name>LY450190</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administer orally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least a 3-month history of erectile dysfunction (ED).

          -  Are able to read, understand and provide signed informed consent.

          -  Have an International Index of Erectile Function-Erectile Function (IIEF-EF) domain
             score that is greater than or equal to 17 and less than 26 at screening.

          -  Have been taking a maximum dose of sildenafil citrate (100 milligram [mg]), vardenafil
             (20 mg), or tadalafil (20 mg) on as needed basis for at least one month prior to
             screening.

          -  Anticipate having the same female sexual partner during the study who is willing to
             participate in the required number of sexual intercourse attempts and complete study
             measures during the study.

          -  Agree to make at least four sexual intercourse attempts during both the 4-week as
             needed run-in period and the 4-week non-drug run-in period.

          -  Agree not to use any other erectile dysfunction (ED) treatment, including herbal
             therapy during the 4-week non-drug, run-in, the double-blind treatment period, the
             open label period and for 96 hours after the end of the study.

        Partner Inclusion Criteria:

          -  Are female and at least 18 years of age at screening.

          -  Anticipate having the same male study subject as her sexual partner during the study.

          -  Able to read, understand and provide signed informed consent.

          -  Agree to make the required number of sexual intercourse attempts with the male sexual
             study partner during the study.

          -  Willing to participate in recording responses to the treatment satisfaction scale.

        Exclusion Criteria:

          -  Have an IIEF-EF domain score of greater than or equal to 26 at screening.

          -  Prior ineffective treatment with (or nonresponder to) any PDE5 Inhibitor

          -  Have previously used or are currently using any PDE5 inhibitor once daily.

          -  Present with ED caused by other primary disorders or ED caused by
             untreated/inadequately treated endocrine disease.

          -  Partner unwilling to complete all study requirements.

          -  History of radical prostatectomy or other pelvic surgery or penile implant, or a
             clinically significant penile deformity, in the opinion of the investigator

          -  Exhibit evidence of clinically significant renal insufficiency or hepatobiliary
             disease, or significant cardiac history as determined by the investigator

          -  Currently receive treatment with nitrates, cancer chemotherapy, or antiandrogens

          -  Have previously completed or withdrawn from this study or any other study
             investigating tadalafil for once-daily use.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lancaster</city>
        <state>California</state>
        <zip>93534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Spring Valley</city>
        <state>California</state>
        <zip>91978</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tarzana</city>
        <state>California</state>
        <zip>91356</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>New Britain</city>
        <state>Connecticut</state>
        <zip>06052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Oviedo</city>
        <state>Florida</state>
        <zip>32765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83646</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nampa</city>
        <state>Idaho</state>
        <zip>83686</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lansing</city>
        <state>Kansas</state>
        <zip>66043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Haverhill</city>
        <state>Massachusetts</state>
        <zip>01830</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08753</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <zip>11530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Concord</city>
        <state>North Carolina</state>
        <zip>28025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lyndhurst</city>
        <state>Ohio</state>
        <zip>44124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bala Cynwyd</city>
        <state>Pennsylvania</state>
        <zip>19004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mt. Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Clinton</city>
        <state>Utah</state>
        <zip>84015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Langley</city>
        <state>British Columbia</state>
        <zip>V3A 4H9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8T 5G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <zip>L7N 3V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>North York</city>
        <state>Ontario</state>
        <zip>M3B 3S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 1N8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7K 7H9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Puerto Rico</country>
  </removed_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2010</study_first_submitted>
  <study_first_submitted_qc>May 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2010</study_first_posted>
  <results_first_submitted>December 3, 2012</results_first_submitted>
  <results_first_submitted_qc>December 3, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 4, 2013</results_first_posted>
  <last_update_submitted>December 3, 2012</last_update_submitted>
  <last_update_submitted_qc>December 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Erectile Dysfunction</keyword>
  <keyword>ED</keyword>
  <keyword>Impotence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tadalafil</mesh_term>
    <mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This study consisted of 4 periods. Period I was a 4-week, as needed, run-in period. Period II was a 4-week, non-drug, wash-out period. Period III was a 12-week (Weeks 0-12), double-blind treatment. Period IV was a 4-week (Weeks 13-16), open-label treatment extension. Only participants completing Period III were eligible to continue into Period IV.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>2.5 mg Titrated to 5 mg Tadalafil</title>
          <description>2.5 milligram (mg) Tadalafil for 4 weeks, followed by 5 mg Tadalafil for 8 weeks during double-blind treatment period.</description>
        </group>
        <group group_id="P2">
          <title>5 mg Tadalafil</title>
          <description>5.0 mg Tadalafil for 12 weeks during double-blind treatment period.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo for 12 weeks during double-blind treatment period.</description>
        </group>
        <group group_id="P4">
          <title>5 mg Tadalafil Open-Label Extension</title>
          <description>5 mg Tadalafil for 4 weeks during open-label treatment extension period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period III (Weeks 0-12)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="207"/>
                <participants group_id="P2" count="207"/>
                <participants group_id="P3" count="209"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="205"/>
                <participants group_id="P2" count="205"/>
                <participants group_id="P3" count="207"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="186"/>
                <participants group_id="P2" count="189"/>
                <participants group_id="P3" count="190"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entry Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period IV (Weeks 13-16)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="562">Three participants who completed Period III chose not to continue into Period IV.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="546"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="552"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entry Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>2.5 mg Titrated to 5 mg Tadalafil</title>
          <description>2.5 milligram (mg) Tadalafil for 4 weeks, followed by 5 mg Tadalafil for 8 weeks during double-blind treatment period.</description>
        </group>
        <group group_id="B2">
          <title>5 mg Tadalafil</title>
          <description>5.0 mg Tadalafil for 12 weeks during double-blind treatment period.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo for 12 weeks during double-blind treatment period.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="207"/>
            <count group_id="B2" value="207"/>
            <count group_id="B3" value="209"/>
            <count group_id="B4" value="623"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.3" spread="10.68"/>
                    <measurement group_id="B2" value="58.1" spread="10.36"/>
                    <measurement group_id="B3" value="57.6" spread="10.17"/>
                    <measurement group_id="B4" value="57.6" spread="10.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="207"/>
                    <measurement group_id="B2" value="207"/>
                    <measurement group_id="B3" value="209"/>
                    <measurement group_id="B4" value="623"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participant</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="199"/>
                    <measurement group_id="B2" value="197"/>
                    <measurement group_id="B3" value="200"/>
                    <measurement group_id="B4" value="596"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participant</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="173"/>
                    <measurement group_id="B2" value="177"/>
                    <measurement group_id="B3" value="167"/>
                    <measurement group_id="B4" value="517"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="199"/>
                    <measurement group_id="B2" value="195"/>
                    <measurement group_id="B3" value="191"/>
                    <measurement group_id="B4" value="585"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puerto Rico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Having an International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score Greater Than or Equal to 26 Through 12-Week Endpoint (Double-Blind Treatment Period)</title>
        <description>Self-reported erectile function over the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (low/no erectile function) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Data presented are the percentage of participants who return to normal erectile function (IIEF-EF domain score â‰¥26) at end of double-blind treatment period (Period III).</description>
        <time_frame>Baseline through 12 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug, had a baseline and at least 1 post-baseline IIEF-EF measurement, excluding those with IIEF-EF domain score â‰¥26 (&quot;normal&quot;) at baseline. Last observation carried forward (LOCF) principle was used.</population>
        <group_list>
          <group group_id="O1">
            <title>2.5 mg Titrated to 5 mg Tadalafil (Period III)</title>
            <description>2.5 milligram (mg) Tadalafil for 4 weeks, followed by 5 mg Tadalafil for 8 weeks during double-blind treatment period (Period III).</description>
          </group>
          <group group_id="O2">
            <title>5 mg Tadalafil (Period III)</title>
            <description>5.0 mg Tadalafil for 12 weeks during double-blind treatment period (Period III).</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Period III)</title>
            <description>Placebo for 12 weeks during double-blind treatment period (Period III).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Having an International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score Greater Than or Equal to 26 Through 12-Week Endpoint (Double-Blind Treatment Period)</title>
          <description>Self-reported erectile function over the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (low/no erectile function) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Data presented are the percentage of participants who return to normal erectile function (IIEF-EF domain score â‰¥26) at end of double-blind treatment period (Period III).</description>
          <population>All randomized participants who received at least 1 dose of study drug, had a baseline and at least 1 post-baseline IIEF-EF measurement, excluding those with IIEF-EF domain score â‰¥26 (&quot;normal&quot;) at baseline. Last observation carried forward (LOCF) principle was used.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="197"/>
                <count group_id="O3" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.7"/>
                    <measurement group_id="O2" value="39.6"/>
                    <measurement group_id="O3" value="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12-Week Endpoint in the International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score</title>
        <description>Self-reported erectile function over the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (low/no erectile function) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug, had a baseline and at least 1 post-baseline IIEF-EF measurement, excluding those with IIEF-EF domain score â‰¥26 (&quot;normal&quot;) at baseline. Last observation carried forward (LOCF) principle was used.</population>
        <group_list>
          <group group_id="O1">
            <title>2.5 mg Titrated to 5 mg Tadalafil (Period III)</title>
            <description>2.5 milligram (mg) Tadalafil for 4 weeks, followed by 5 mg Tadalafil for 8 weeks during double-blind treatment period (Period III).</description>
          </group>
          <group group_id="O2">
            <title>5 mg Tadalafil (Period III)</title>
            <description>5.0 mg Tadalafil for 12 weeks during double-blind treatment period (Period III).</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Period III)</title>
            <description>Placebo for 12 weeks during double-blind treatment period (Period III).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12-Week Endpoint in the International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score</title>
          <description>Self-reported erectile function over the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (low/no erectile function) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.</description>
          <population>All randomized participants who received at least 1 dose of study drug, had a baseline and at least 1 post-baseline IIEF-EF measurement, excluding those with IIEF-EF domain score â‰¥26 (&quot;normal&quot;) at baseline. Last observation carried forward (LOCF) principle was used.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="197"/>
                <count group_id="O3" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" spread="0.49"/>
                    <measurement group_id="O2" value="8.1" spread="0.49"/>
                    <measurement group_id="O3" value="1.8" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>6.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.69</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>6.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.68</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12-Week Endpoint in the International Index of Erectile Function - Intercourse Satisfaction (IIEF-IS) Domain Score</title>
        <description>Self-reported intercourse satisfaction over the past 4 weeks. IIEF-IS is the sum of Questions 6, 7 and 8 of the IIEF. Scores range from 0 (low/no satisfaction) to 5 (high satisfaction) for each question, with the total possible score for the 3 questions of 0 to 15. Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug, had a baseline and at least 1 post-baseline IIEF-IS measurement, excluding those with International Index of Erectile Function - Erectile Function (IIEF-EF) domain score â‰¥26 (&quot;normal&quot;) at baseline. Last observation carried forward (LOCF) principle was used.</population>
        <group_list>
          <group group_id="O1">
            <title>2.5 mg Titrated to 5 mg Tadalafil (Period III)</title>
            <description>2.5 milligram (mg) Tadalafil for 4 weeks, followed by 5 mg Tadalafil for 8 weeks during double-blind treatment period (Period III).</description>
          </group>
          <group group_id="O2">
            <title>5 mg Tadalafil (Period III)</title>
            <description>5.0 mg Tadalafil for 12 weeks during double-blind treatment period (Period III).</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Period III)</title>
            <description>Placebo for 12 weeks during double-blind treatment period (Period III).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12-Week Endpoint in the International Index of Erectile Function - Intercourse Satisfaction (IIEF-IS) Domain Score</title>
          <description>Self-reported intercourse satisfaction over the past 4 weeks. IIEF-IS is the sum of Questions 6, 7 and 8 of the IIEF. Scores range from 0 (low/no satisfaction) to 5 (high satisfaction) for each question, with the total possible score for the 3 questions of 0 to 15. Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.</description>
          <population>All randomized participants who received at least 1 dose of study drug, had a baseline and at least 1 post-baseline IIEF-IS measurement, excluding those with International Index of Erectile Function - Erectile Function (IIEF-EF) domain score â‰¥26 (&quot;normal&quot;) at baseline. Last observation carried forward (LOCF) principle was used.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="197"/>
                <count group_id="O3" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="0.21"/>
                    <measurement group_id="O2" value="2.6" spread="0.21"/>
                    <measurement group_id="O3" value="0.6" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>2.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.29</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>2.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.29</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12-Week Endpoint in the International Index of Erectile Function - Overall Satisfaction (IIEF-OS) Domain Score</title>
        <description>Self-reported overall satisfaction over the past 4 weeks. IIEF-OS is the sum of Questions 13 and 14; each question scored as 1 (low/no satisfaction) through 5 (high satisfaction) with total subscore for the 2 questions of 2 to 10. Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug, had a baseline and at least 1 post-baseline IIEF-OS measurement, excluding those with International Index of Erectile Function - Erectile Function (IIEF-EF) domain score â‰¥26 (&quot;normal&quot;) at baseline. Last observation carried forward (LOCF) principle was used.</population>
        <group_list>
          <group group_id="O1">
            <title>2.5 mg Titrated to 5 mg Tadalafil (Period III)</title>
            <description>2.5 milligram (mg) Tadalafil for 4 weeks, followed by 5 mg Tadalafil for 8 weeks during double-blind treatment period (Period III).</description>
          </group>
          <group group_id="O2">
            <title>5 mg Tadalafil (Period III)</title>
            <description>5.0 mg Tadalafil for 12 weeks during double-blind treatment period (Period III).</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Period III)</title>
            <description>Placebo for 12 weeks during double-blind treatment period (Period III).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12-Week Endpoint in the International Index of Erectile Function - Overall Satisfaction (IIEF-OS) Domain Score</title>
          <description>Self-reported overall satisfaction over the past 4 weeks. IIEF-OS is the sum of Questions 13 and 14; each question scored as 1 (low/no satisfaction) through 5 (high satisfaction) with total subscore for the 2 questions of 2 to 10. Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.</description>
          <population>All randomized participants who received at least 1 dose of study drug, had a baseline and at least 1 post-baseline IIEF-OS measurement, excluding those with International Index of Erectile Function - Erectile Function (IIEF-EF) domain score â‰¥26 (&quot;normal&quot;) at baseline. Last observation carried forward (LOCF) principle was used.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="197"/>
                <count group_id="O3" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="0.16"/>
                    <measurement group_id="O2" value="2.4" spread="0.16"/>
                    <measurement group_id="O3" value="0.6" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.23</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.22</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12-Week in Percentage of &quot;Yes&quot; Responses to Sexual Encounter Profile (SEP) Questions 1-5</title>
        <description>Assessed was the mean change from baseline in the percentage of Yes responses to the SEP diary Questions 1-5. Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug, had a baseline and at least 1 post-baseline SEP Questions assessment, excluding those with International Index of Erectile Function - Erectile Function (IIEF-EF) domain score â‰¥26 (&quot;normal&quot;) at baseline. Last observation carried forward (LOCF) principle was used.</population>
        <group_list>
          <group group_id="O1">
            <title>2.5 mg Titrated to 5 mg Tadalafil (Period III)</title>
            <description>2.5 milligram (mg) Tadalafil for 4 weeks, followed by 5 mg Tadalafil for 8 weeks during double-blind treatment period (Period III).</description>
          </group>
          <group group_id="O2">
            <title>5 mg Tadalafil (Period III)</title>
            <description>5.0 mg Tadalafil for 12 weeks during double-blind treatment period (Period III).</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Period III)</title>
            <description>Placebo for 12 weeks during double-blind treatment period (Period III).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12-Week in Percentage of &quot;Yes&quot; Responses to Sexual Encounter Profile (SEP) Questions 1-5</title>
          <description>Assessed was the mean change from baseline in the percentage of Yes responses to the SEP diary Questions 1-5. Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.</description>
          <population>All randomized participants who received at least 1 dose of study drug, had a baseline and at least 1 post-baseline SEP Questions assessment, excluding those with International Index of Erectile Function - Erectile Function (IIEF-EF) domain score â‰¥26 (&quot;normal&quot;) at baseline. Last observation carried forward (LOCF) principle was used.</population>
          <units>percentage of &quot;yes&quot; responses</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="195"/>
                <count group_id="O3" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Question 1: Able to Achieve Erection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" spread="1.63"/>
                    <measurement group_id="O2" value="11.4" spread="1.62"/>
                    <measurement group_id="O3" value="1.8" spread="1.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Question 2: Able to Insert</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2" spread="2.25"/>
                    <measurement group_id="O2" value="26.1" spread="2.23"/>
                    <measurement group_id="O3" value="6.9" spread="2.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Question 3: Successful Intercourse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.3" spread="2.52"/>
                    <measurement group_id="O2" value="39.4" spread="2.50"/>
                    <measurement group_id="O3" value="12.6" spread="2.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Question 4: Satisfied with Hardness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.2" spread="2.73"/>
                    <measurement group_id="O2" value="42.8" spread="2.70"/>
                    <measurement group_id="O3" value="11.5" spread="2.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Question 5: Overall Satisfaction with Experience</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.6" spread="2.70"/>
                    <measurement group_id="O2" value="41.2" spread="2.68"/>
                    <measurement group_id="O3" value="10.6" spread="2.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Question 1. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>10.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.28</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Question 1. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>9.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.26</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Question 2. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>19.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.14</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Question 2. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>19.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.12</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Question 3. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>24.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.53</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Question 3. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>26.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.50</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Question 4. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>32.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.82</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Question 4. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>31.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.79</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Question 5. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>33.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.78</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Question 5. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>30.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.75</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12-Week Endpoint in Treatment Satisfaction Scale (TSS) - Patient</title>
        <description>The TSS measured participant satisfaction with treatment based on a 13-item questionnaire. The overall score for each of five TSS domains (confidence to complete sexual activity, ease of erection, pleasure from sexual activity, erectile function satisfaction, and satisfaction with orgasm) was converted to a 0-100 scale with higher numbers on the scale indicating greater satisfaction. Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug, had a baseline and at least 1 post-baseline TSS measurement, excluding those with International Index of Erectile Function - Erectile Function (IIEF-EF) domain score â‰¥26 (&quot;normal&quot;) at baseline. Last observation carried forward (LOCF) principle was used.</population>
        <group_list>
          <group group_id="O1">
            <title>2.5 mg Titrated to 5 mg Tadalafil (Period III)</title>
            <description>2.5 milligram (mg) Tadalafil for 4 weeks, followed by 5 mg Tadalafil for 8 weeks during double-blind treatment period (Period III).</description>
          </group>
          <group group_id="O2">
            <title>5 mg Tadalafil (Period III)</title>
            <description>5.0 mg Tadalafil for 12 weeks during double-blind treatment period (Period III).</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Period III)</title>
            <description>Placebo for 12 weeks during double-blind treatment period (Period III).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12-Week Endpoint in Treatment Satisfaction Scale (TSS) - Patient</title>
          <description>The TSS measured participant satisfaction with treatment based on a 13-item questionnaire. The overall score for each of five TSS domains (confidence to complete sexual activity, ease of erection, pleasure from sexual activity, erectile function satisfaction, and satisfaction with orgasm) was converted to a 0-100 scale with higher numbers on the scale indicating greater satisfaction. Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.</description>
          <population>All randomized participants who received at least 1 dose of study drug, had a baseline and at least 1 post-baseline TSS measurement, excluding those with International Index of Erectile Function - Erectile Function (IIEF-EF) domain score â‰¥26 (&quot;normal&quot;) at baseline. Last observation carried forward (LOCF) principle was used.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="189"/>
                <count group_id="O2" value="189"/>
                <count group_id="O3" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Confidence to complete sexual activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.0" spread="1.78"/>
                    <measurement group_id="O2" value="29.2" spread="1.78"/>
                    <measurement group_id="O3" value="3.8" spread="1.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ease of erection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0" spread="1.69"/>
                    <measurement group_id="O2" value="24.7" spread="1.69"/>
                    <measurement group_id="O3" value="4.1" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pleasure from sexual activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.6" spread="1.58"/>
                    <measurement group_id="O2" value="22.7" spread="1.58"/>
                    <measurement group_id="O3" value="3.3" spread="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erectile function satisfaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.0" spread="1.82"/>
                    <measurement group_id="O2" value="33.6" spread="1.81"/>
                    <measurement group_id="O3" value="4.9" spread="1.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfaction with orgasm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.6" spread="1.90"/>
                    <measurement group_id="O2" value="26.3" spread="1.89"/>
                    <measurement group_id="O3" value="6.2" spread="1.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for confidence to complete sexual activity. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>23.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.49</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for confidence to complete sexual activity. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>25.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.48</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for ease of erection. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>19.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.36</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for ease of erection. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>20.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.35</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for pleasure from sexual activity. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>19.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.21</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for pleasure from sexual activity. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>19.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.20</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for erectile function satisfaction. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>26.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.54</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for erectile function satisfaction. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>28.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.53</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for satisfaction with orgasm. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>19.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.65</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for satisfaction with orgasm. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>20.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.64</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Satisfaction Scale (TSS) - Patient Satisfaction With Medication Score at Week 12 Endpoint</title>
        <description>The TSS - patient satisfaction with medication measured participant satisfaction with treatment based on a 13-item questionnaire. The overall score was converted to a 0-100 scale with higher numbers on the scale indicating greater satisfaction. Satisfaction with medication was analyzed using analysis of covariance (ANOVA). The model included factors of study, treatment group, and pooled site within study.</description>
        <time_frame>Week 12</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug, had a baseline and at least 1 post-baseline participant's satisfaction with medication measurement, excluding those with IIEF-EF domain score â‰¥26 (&quot;normal&quot;) at baseline. Last observation carried forward (LOCF) principle was used.</population>
        <group_list>
          <group group_id="O1">
            <title>2.5 mg Titrated to 5 mg Tadalafil (Period III)</title>
            <description>2.5 milligram (mg) Tadalafil for 4 weeks, followed by 5 mg Tadalafil for 8 weeks during double-blind treatment period (Period III).</description>
          </group>
          <group group_id="O2">
            <title>5 mg Tadalafil (Period III)</title>
            <description>5.0 mg Tadalafil for 12 weeks during double-blind treatment period (Period III).</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Period III)</title>
            <description>Placebo for 12 weeks during double-blind treatment period (Period III).</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Satisfaction Scale (TSS) - Patient Satisfaction With Medication Score at Week 12 Endpoint</title>
          <description>The TSS - patient satisfaction with medication measured participant satisfaction with treatment based on a 13-item questionnaire. The overall score was converted to a 0-100 scale with higher numbers on the scale indicating greater satisfaction. Satisfaction with medication was analyzed using analysis of covariance (ANOVA). The model included factors of study, treatment group, and pooled site within study.</description>
          <population>All randomized participants who received at least 1 dose of study drug, had a baseline and at least 1 post-baseline participant's satisfaction with medication measurement, excluding those with IIEF-EF domain score â‰¥26 (&quot;normal&quot;) at baseline. Last observation carried forward (LOCF) principle was used.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="189"/>
                <count group_id="O2" value="189"/>
                <count group_id="O3" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.7" spread="1.98"/>
                    <measurement group_id="O2" value="55.9" spread="1.98"/>
                    <measurement group_id="O3" value="24.8" spread="1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>ANOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>28.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.77</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>ANOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>31.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.76</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12-Week Endpoint in the International Index of Erectile Function (IIEF) Question 15 (Sexual Confidence)</title>
        <description>Self-reported erectile function over the past 4 weeks. Question 15, confidence in the ability to get an erection, is scored from 1 (very low confidence) to 5 (very high confidence). Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug, had a baseline and at least 1 post-baseline IIEF question 15 (Sexual Confidence) assessment, excluding those with IIEF-EF domain score â‰¥26 (&quot;normal&quot;) at baseline. Last observation carried forward (LOCF) principle was used.</population>
        <group_list>
          <group group_id="O1">
            <title>2.5 mg Titrated to 5 mg Tadalafil (Period III)</title>
            <description>2.5 milligram (mg) Tadalafil for 4 weeks, followed by 5 mg Tadalafil for 8 weeks during double-blind treatment period (Period III).</description>
          </group>
          <group group_id="O2">
            <title>5 mg Tadalafil (Period III)</title>
            <description>5.0 mg Tadalafil for 12 weeks during double-blind treatment period (Period III).</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Period III)</title>
            <description>Placebo for 12 weeks during double-blind treatment period (Period III).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12-Week Endpoint in the International Index of Erectile Function (IIEF) Question 15 (Sexual Confidence)</title>
          <description>Self-reported erectile function over the past 4 weeks. Question 15, confidence in the ability to get an erection, is scored from 1 (very low confidence) to 5 (very high confidence). Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.</description>
          <population>All randomized participants who received at least 1 dose of study drug, had a baseline and at least 1 post-baseline IIEF question 15 (Sexual Confidence) assessment, excluding those with IIEF-EF domain score â‰¥26 (&quot;normal&quot;) at baseline. Last observation carried forward (LOCF) principle was used.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="197"/>
                <count group_id="O3" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.08"/>
                    <measurement group_id="O2" value="1.3" spread="0.08"/>
                    <measurement group_id="O3" value="0.3" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12-Week Endpoint in Treatment Satisfaction Scale (TSS) - Partner</title>
        <description>The TSS measured participant's partner satisfaction with treatment based on a 13-item questionnaire. The overall score for each of five TSS domains (confidence to complete sexual activity, ease of erection, pleasure from sexual activity, erectile function satisfaction, and satisfaction with orgasm) was converted to a 0-100 scale with higher numbers on the scale indicating greater satisfaction. Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug, had a baseline and at least 1 post-baseline partner's TSS measurement, excluding those with IIEF-EF domain score â‰¥26 (&quot;normal&quot;) at baseline. Last observation carried forward (LOCF) principle was used.</population>
        <group_list>
          <group group_id="O1">
            <title>2.5 mg Titrated to 5 mg Tadalafil (Period III)</title>
            <description>2.5 milligram (mg) Tadalafil for 4 weeks, followed by 5 mg Tadalafil for 8 weeks during double-blind treatment period (Period III).</description>
          </group>
          <group group_id="O2">
            <title>5 mg Tadalafil (Period III)</title>
            <description>5.0 mg Tadalafil for 12 weeks during double-blind treatment period (Period III).</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Period III)</title>
            <description>Placebo for 12 weeks during double-blind treatment period (Period III).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12-Week Endpoint in Treatment Satisfaction Scale (TSS) - Partner</title>
          <description>The TSS measured participant's partner satisfaction with treatment based on a 13-item questionnaire. The overall score for each of five TSS domains (confidence to complete sexual activity, ease of erection, pleasure from sexual activity, erectile function satisfaction, and satisfaction with orgasm) was converted to a 0-100 scale with higher numbers on the scale indicating greater satisfaction. Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.</description>
          <population>All randomized participants who received at least 1 dose of study drug, had a baseline and at least 1 post-baseline partner's TSS measurement, excluding those with IIEF-EF domain score â‰¥26 (&quot;normal&quot;) at baseline. Last observation carried forward (LOCF) principle was used.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="186"/>
                <count group_id="O3" value="187"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Confidence to complete sexual activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.7" spread="2.01"/>
                    <measurement group_id="O2" value="27.2" spread="1.99"/>
                    <measurement group_id="O3" value="2.0" spread="1.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ease of erection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.1" spread="1.76"/>
                    <measurement group_id="O2" value="25.3" spread="1.75"/>
                    <measurement group_id="O3" value="0.7" spread="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pleasure from sexual activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2" spread="1.69"/>
                    <measurement group_id="O2" value="18.5" spread="1.68"/>
                    <measurement group_id="O3" value="1.3" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erectile function satisfaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6" spread="1.84"/>
                    <measurement group_id="O2" value="28.5" spread="1.83"/>
                    <measurement group_id="O3" value="3.4" spread="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfaction with orgasm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7" spread="2.06"/>
                    <measurement group_id="O2" value="21.0" spread="2.05"/>
                    <measurement group_id="O3" value="3.6" spread="2.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for confidence to complete sexual activity. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>21.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.81</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for confidence to complete sexual activity. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>25.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.78</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for ease of erection. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>22.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.46</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for ease of erection. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>24.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.44</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for pleasure from sexual activity. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>16.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.37</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for pleasure from sexual activity. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>17.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.35</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for erectile function satisfaction. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>25.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.57</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for erectile function satisfaction. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>25.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.56</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for satisfaction with orgasm. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>15.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.88</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for satisfaction with orgasm. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>17.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.86</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Satisfaction Scale (TSS) â€“ Partner Satisfaction With Medication Score at Week 12 Endpoint</title>
        <description>The TSS - partner satisfaction with medication measured participant's partner satisfaction with treatment based on a 13-item questionnaire. The overall score was converted to a 0-100 scale with higher numbers on the scale indicating greater satisfaction. Satisfaction with medication was analyzed using analysis of covariance (ANOVA). The model included factors of study, treatment group, and pooled site within study.</description>
        <time_frame>Week 12</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug, had a baseline and at least 1 post-baseline partner's satisfaction with medication measurement, excluding those with IIEF-EF domain score â‰¥26 (&quot;normal&quot;) at baseline. Last observation carried forward (LOCF) principle was used.</population>
        <group_list>
          <group group_id="O1">
            <title>2.5 mg Titrated to 5 mg Tadalafil (Period III)</title>
            <description>2.5 milligram (mg) Tadalafil for 4 weeks, followed by 5 mg Tadalafil for 8 weeks during double-blind treatment period (Period III).</description>
          </group>
          <group group_id="O2">
            <title>5 mg Tadalafil (Period III)</title>
            <description>5.0 mg Tadalafil for 12 weeks during double-blind treatment period (Period III).</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Period III)</title>
            <description>Placebo for 12 weeks during double-blind treatment period (Period III).</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Satisfaction Scale (TSS) â€“ Partner Satisfaction With Medication Score at Week 12 Endpoint</title>
          <description>The TSS - partner satisfaction with medication measured participant's partner satisfaction with treatment based on a 13-item questionnaire. The overall score was converted to a 0-100 scale with higher numbers on the scale indicating greater satisfaction. Satisfaction with medication was analyzed using analysis of covariance (ANOVA). The model included factors of study, treatment group, and pooled site within study.</description>
          <population>All randomized participants who received at least 1 dose of study drug, had a baseline and at least 1 post-baseline partner's satisfaction with medication measurement, excluding those with IIEF-EF domain score â‰¥26 (&quot;normal&quot;) at baseline. Last observation carried forward (LOCF) principle was used.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="186"/>
                <count group_id="O3" value="187"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.5" spread="1.97"/>
                    <measurement group_id="O2" value="55.7" spread="1.96"/>
                    <measurement group_id="O3" value="27.5" spread="1.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>ANOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>25.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.76</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>ANOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>28.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.74</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Having International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score Greater Than or Equal to 26 From 12 to 16 Weeks</title>
        <description>Self-reported erectile function over the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (low/no erectile function) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Data presented are the percentage of participants who return to normal erectile function (IIEF-EF domain score â‰¥26) at end of open-label extension treatment period (Period IV).</description>
        <time_frame>12 weeks through 16 weeks</time_frame>
        <population>All participants who were entered the open-label treatment, received at least 1 dose of study drug during open-label treatment, had Week 12 and at least 1 IIEF-EF measurement during open-label treatment, excluding those with IIEF-EF domain score â‰¥26 (&quot;normal&quot;) at baseline. Last observation carried forward (LOCF) principle was used.</population>
        <group_list>
          <group group_id="O1">
            <title>2.5 mg Titrated to 5 mg Tadalafil (Period IV)</title>
            <description>5.0 milligram (mg) Tadalafil for 4 weeks during open-label extension treatment period (Period IV).</description>
          </group>
          <group group_id="O2">
            <title>5 mg Tadalafil (Period IV)</title>
            <description>5.0 mg Tadalafil for 4 weeks during open-label extension treatment period (Period IV).</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Period IV)</title>
            <description>5.0 mg Tadalafil for 4 weeks during open-label extension treatment period (Period IV).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Having International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score Greater Than or Equal to 26 From 12 to 16 Weeks</title>
          <description>Self-reported erectile function over the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (low/no erectile function) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Data presented are the percentage of participants who return to normal erectile function (IIEF-EF domain score â‰¥26) at end of open-label extension treatment period (Period IV).</description>
          <population>All participants who were entered the open-label treatment, received at least 1 dose of study drug during open-label treatment, had Week 12 and at least 1 IIEF-EF measurement during open-label treatment, excluding those with IIEF-EF domain score â‰¥26 (&quot;normal&quot;) at baseline. Last observation carried forward (LOCF) principle was used.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="179"/>
                <count group_id="O3" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.5"/>
                    <measurement group_id="O2" value="59.8"/>
                    <measurement group_id="O3" value="62.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From 12 Weeks to 16 Weeks in Participant's International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score</title>
        <description>Self-reported erectile function over the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (low/no erectile function) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function.</description>
        <time_frame>12 weeks and 16 weeks</time_frame>
        <population>All participants who were entered the open-label treatment, received at least 1 dose of study drug during open-label treatment, had Week 12 and at least 1 IIEF-EF measurement during open-label treatment, excluding those with IIEF-EF domain score â‰¥26 (&quot;normal&quot;) at baseline. Last observation carried forward (LOCF) principle was used.</population>
        <group_list>
          <group group_id="O1">
            <title>2.5 mg Titrated to 5 mg Tadalafil (Period IV)</title>
            <description>5.0 milligram (mg) Tadalafil for 4 weeks during open-label extension treatment period (Period IV).</description>
          </group>
          <group group_id="O2">
            <title>5 mg Tadalafil (Period IV)</title>
            <description>5.0 mg Tadalafil for 4 weeks during open-label extension treatment period (Period IV).</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Period IV)</title>
            <description>5.0 mg Tadalafil for 4 weeks during open-label extension treatment period (Period IV).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From 12 Weeks to 16 Weeks in Participant's International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score</title>
          <description>Self-reported erectile function over the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (low/no erectile function) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function.</description>
          <population>All participants who were entered the open-label treatment, received at least 1 dose of study drug during open-label treatment, had Week 12 and at least 1 IIEF-EF measurement during open-label treatment, excluding those with IIEF-EF domain score â‰¥26 (&quot;normal&quot;) at baseline. Last observation carried forward (LOCF) principle was used.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="179"/>
                <count group_id="O3" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>End of Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.4" spread="6.71"/>
                    <measurement group_id="O2" value="22.5" spread="7.07"/>
                    <measurement group_id="O3" value="16.0" spread="7.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.1" spread="6.44"/>
                    <measurement group_id="O2" value="24.2" spread="6.46"/>
                    <measurement group_id="O3" value="24.4" spread="6.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison of Week 16 to Week 12. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>Paired t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison of Week 16 to Week 12. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>Paired t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison of Week 16 to Week 12. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>Paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Week 12 to Week 16 Percentage of &quot;Yes&quot; Responses to Sexual Encounter Profile (SEP) Questions 3</title>
        <description>Assessed the percentage of Yes responses to the SEP diary Question 3 &quot;Did your erection last long enough for you to have successful intercourse?&quot; from Week 12 (end of double-Blind treatment) to Week 16 (end of open-label treatment).</description>
        <time_frame>12 weeks and 16 weeks</time_frame>
        <population>All participants who were entered the open-label treatment, received at least 1 dose of study drug during open-label treatment, had Week 12 and at least 1 SEP diary Question 3 measurement during open-label treatment, excluding those with IIEF-EF domain score â‰¥26 (&quot;normal&quot;) at baseline. Last observation carried forward (LOCF) principle was used.</population>
        <group_list>
          <group group_id="O1">
            <title>2.5 mg Titrated to 5 mg Tadalafil (Period IV)</title>
            <description>5.0 milligram (mg) Tadalafil for 4 weeks during open-label extension treatment period (Period IV).</description>
          </group>
          <group group_id="O2">
            <title>5 mg Tadalafil (Period IV)</title>
            <description>5.0 mg Tadalafil for 4 weeks during open-label extension treatment period (Period IV).</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Period IV)</title>
            <description>5.0 mg Tadalafil for 4 weeks during open-label extension treatment period (Period IV).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Week 12 to Week 16 Percentage of &quot;Yes&quot; Responses to Sexual Encounter Profile (SEP) Questions 3</title>
          <description>Assessed the percentage of Yes responses to the SEP diary Question 3 &quot;Did your erection last long enough for you to have successful intercourse?&quot; from Week 12 (end of double-Blind treatment) to Week 16 (end of open-label treatment).</description>
          <population>All participants who were entered the open-label treatment, received at least 1 dose of study drug during open-label treatment, had Week 12 and at least 1 SEP diary Question 3 measurement during open-label treatment, excluding those with IIEF-EF domain score â‰¥26 (&quot;normal&quot;) at baseline. Last observation carried forward (LOCF) principle was used.</population>
          <units>percentage of &quot;yes&quot; responses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="177"/>
                <count group_id="O3" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>End of Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.3" spread="38.25"/>
                    <measurement group_id="O2" value="69.0" spread="37.88"/>
                    <measurement group_id="O3" value="43.1" spread="39.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" spread="34.49"/>
                    <measurement group_id="O2" value="75.5" spread="34.89"/>
                    <measurement group_id="O3" value="80.0" spread="34.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>Comparison of Week 16 to Week 12. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>Paired t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>Comparison of Week 16 to Week 12. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>Paired t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison of Week 16 to Week 12. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.</p_value_desc>
            <method>Paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>2.5 mg Titrated to 5 mg Tadalafil</title>
          <description>2.5 milligram (mg) Tadalafil for 4 weeks, followed by 5 mg Tadalafil for 8 weeks during double-blind treatment period.</description>
        </group>
        <group group_id="E2">
          <title>5 mg Tadalafil</title>
          <description>5.0 mg Tadalafil for 12 weeks during double-blind treatment period.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo for 12 weeks during double-blind treatment period.</description>
        </group>
        <group group_id="E4">
          <title>5 mg Tadalafil Open-Label Extension</title>
          <description>5 mg Tadalafil for 4 weeks during open-label treatment extension period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="546"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="546"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="546"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="546"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="207"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="546"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="546"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="546"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing impaired</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Motion sickness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="546"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="205"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Retching</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Suprapubic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="205"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Infected bites</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Pneumonia primary atypical</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Prostate infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="205"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Exposure via father</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Cytology abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="205"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Joint hyperextension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Metatarsalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Musculoskeletal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="205"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="205"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="207"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Restless legs syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Sensory disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Chromaturia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Genital rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Nipple pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Organic erectile dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Paraesthesia of genital male</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Penile discharge</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Spermatocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Testicular pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Pharyngeal inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Upper-airway cough syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Rosacea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="546"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Anal polypectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Blepharoplasty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Cataract operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Dental care</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Endodontic procedure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Knee operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Medical device removal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Tooth repair</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Umbilical hernia repair</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Vasectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="207"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
              <event>
                <sub_title>Orthostatic hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="546"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

